Page 5 - Davide Olson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Psychedelic-Like Drug Lacking Hallucinogenic Side Effects Identified with New Sensor Psychedelic-Like Drug Lacking Hallucinogenic Side Effects Identified with New Sensor This is a representative image of cultured dissociated hippocampal neurons transiently expressing psychLight1 and psychLight2. [Chunyang Dong, Calvin Ly, and Joanne Ly at UC Davis] April 28, 2021 Share At the University of California (UC), Davis, psychLight just dropped in to see what condition serotonin dynamics was in. And psychLight didn’t even have to fly eight miles high. Upon binding serotonin or a hallucinogenic lig...

Share: BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD. The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University of California, Davis, reveals DLX-1—a new compound inspired by the chemical structures of common psychedelic substances that dem...

 E-Mail IMAGE: This is a representative image of cultured dissociated hippocampal neurons transiently expressing psychLight1 and psychLight2. Scale bar, 20 mm. view more  Credit: Calvin Ly Psychedelic drugs have shown promise for treating neuropsychiatric disorders such as depression and posttraumatic stress disorder. However, due to their hallucinatory side effects, some researchers are trying to identify drugs that could offer the benefits of psychedelics without causing hallucinations. In the journal Cell on April 28, researchers report they have identified one such drug through...

Share this article Share this article BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD. The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University of California, Davis, reveals DLX-1—a new compound inspired by the chemical structures of common ...

A newly-identified 'psychedelic-like drug' doesn't cause hallucinogenic side effects, scientists reveal. AAZ-A-154 is a 'previously unstudied' molecule that has the potential to act on beneficial pathways in the brain without causing hallucinations.  It stimulates receptors for serotonin – a key hormone sent between nerve cells in our brain that stabilises our mood, well-being and happiness.  In experiments on mice, AAZ-A-154 produced rapid and long-lasting antidepressant-like effects after a single dose, the US researchers found – and, if synthesised, could be an effective treatment fo...